ATR and ovarian carcinoma: These studies provided preclinical in vitro and in vivo data to support moving combination PARPi–ATRi forward into the clinic, and have led to the trial design for the Combination ATR with PARP Inhibition or the CAPRI trial which will be evaluating AZD6738 and olaparib for recurrent ovarian cancer.